- Home
- PLMR vs NRIX Comparison
PLMR vs NRIX Comparison
Compare PLMR & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLMR | NRIX |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.8B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLMR | NRIX |
|---|---|---|
| Price | $158.53 | $16.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $159.17 | $33.86 |
| AVG Volume (30 Days) | 238.3K | ★ 3.2M |
| Earning Date | 11-04-2026 | 10-12-2026 |
| Dividend Yield | ★ 1.25% | N/A |
| EPS Growth | ★ 60.04 | N/A |
| EPS | ★ 3.51 | 3.26 |
| Revenue | ★ $875,967,000.00 | $76,987,000.00 |
| Revenue This Year | $35.94 | $786.93 |
| Revenue Next Year | $24.29 | N/A |
| P/E Ratio | $41.04 | ★ $4.89 |
| Revenue Growth | 58.16 | ★ 99.31 |
| 52 Week Low | $100.81 | $11.67 |
| 52 Week High | $147.62 | $28.23 |
Technical Indicators
Market Signals| Indicator | PLMR | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 60.43 | 21.15 |
| Support Level | $117.17 | $14.63 |
| Resistance Level | $144.81 | $17.47 |
| Average True Range (ATR) | 4.16 | 1.25 |
| MACD | 0.45 | -0.55 |
| Stochastic Oscillator | 81.29 | 8.86 |
Price Performance
Historical ComparisonAbout PLMR Palomar Holdings Inc.
Palomar Holdings Inc that provides property and casualty insurance products to individuals and businesses. It provides insurance products serving five categories: Earthquake, Inland Marine and Other Property, Casualty, Fronting, and Crop. Company distribute products through multiple channels, including retail agents, program administrators, wholesale brokers, and partnerships with other insurance companies. The company's Earthquake product generate high premium.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.